An ICU decision: tracheostomy, or antithrombotics?

Short answer

In the first 30 days after coronary stent placement—especially for an acute myocardial infarction—the balance of risks strongly favours continuing antithrombotic therapy and maintaining endotracheal intubation (Option 2). Elective tracheostomy should be deferred until the highest-risk period for stent thrombosis has passed, unless an immediate, life-threatening airway or secretion-management crisis forces intervention. If tracheostomy becomes unavoidable before that window closes, it should be performed with aspirin continued and the P2Y₁₂ inhibitor held for the shortest guideline-recommended duration, not with a complete interruption of all antithrombotics.

Why continuing antithrombotics and delaying tracheostomy is preferred

1. Stent thrombosis risk dwarfs the early risks of prolonged intubation

• Stent thrombosis is most frequent in the first 30 days after drug-eluting stent (DES) implantation, with the majority of events in the first 1–2 weeks [8][15]. Premature discontinuation of the P2Y₁₂ inhibitor during this period is strongly associated with early stent thrombosis and is described as carrying an unacceptable risk [8][15]. Reported mortality varies across cohorts but is substantial [5][15].
• Current ACC/AHA and ESC guidelines recommend uninterrupted DAPT for at least 1 month after bare-metal stent placement and 6–12 months after DES for acute coronary syndrome, unless high bleeding risk mandates a shorter course [8][10]. If a procedure is unavoidable, aspirin should be continued and the P2Y₁₂ inhibitor held for the minimum washout (clopidogrel 5 days, ticagrelor 3–5 days, prasugrel 7 days), restarted within 24–48 hours post-procedure [30][31][41][43].
• The immediate, life-threatening danger of stent thrombosis therefore outweighs the harms of an extra 1–3 weeks of translaryngeal intubation, which are real but generally manageable with meticulous bundle-based care.

2. Prolonged intubation carries meaningful but slower-accumulating risks

• Complications include ventilator-associated pneumonia, laryngeal injury, subglottic stenosis, sinusitis, increased sedation requirements, and ICU-acquired weakness. (general standard-of-care; confirm against current guidelines) Extubation failure is common in comatose patients with impaired airway reflexes, even when they pass a spontaneous breathing trial. (general standard-of-care)
• Trials and meta-analyses of early tracheostomy (≤7–10 days) show it may reduce ventilator days and ICU stay but does not improve mortality [17][24]. The TRACMAN RCT found no difference in 30-day or longer-term mortality between early and deferred tracheostomy [24][25]; SETPOINT2 in severe stroke showed no improvement in survival without severe disability with early timing [18][19][21]. Here, the "early" tracheostomy window coincides with the period of maximal stent-thrombosis danger, making delay the safer default.

3. Tracheostomy bleeding risk is manageable on aspirin alone but rises sharply on full DAPT

• Tracheostomy is a high-bleeding-risk procedure. (general standard-of-care) Observational data indicate acceptable bleeding rates on aspirin monotherapy, but continuing a P2Y₁₂ inhibitor or therapeutic anticoagulation raises major bleeding rates and the risk of airway-compromising haematoma [28].
• Many centres therefore continue aspirin, hold the P2Y₁₂ inhibitor for the minimum required time, and use experienced operators when tracheostomy must be performed early [29][40][43]. Guidelines strongly caution that stopping all antiplatelet therapy soon after PCI carries a high risk of catastrophic stent thrombosis [8][29][38].

Clinical factors that should guide the decision

1. Time since stent placement — the first 30 days are the highest-risk period for stent thrombosis [8][29][38]; after 30 days (BMS) or 3–6 months (DES) the calculus shifts and tracheostomy can be considered with a brief, controlled P2Y₁₂ interruption.
2. Stent and antithrombotic characteristics — DES vs. BMS, lesion complexity, the specific P2Y₁₂ agent, and any concomitant anticoagulation all modulate risk; validated risk scores help quantify the trade-off. (general standard-of-care)
3. Neurological prognosis — post-arrest neuroprognostication is multimodal and typically deferred until at least 72 hours after return of spontaneous circulation. (general standard-of-care)
4. Airway and pulmonary status — high secretion burden, recurrent aspiration, or intolerance of reduced support may force an earlier decision. (general standard-of-care)
5. Multidisciplinary coordination — interventional cardiology, critical care, neurology, and the procedural team must align on antithrombotic management, timing, and goals of care.

Practical synthesis

Within the first 30 days after stenting for acute MI: continue DAPT, maintain intubation, optimise pulmonary hygiene, minimise sedation, and pursue structured neuroprognostication. If tracheostomy becomes unavoidable earlier, perform it with aspirin continued, the P2Y₁₂ inhibitor held for the minimum washout, and restarted as soon as haemostasis is secure — typically within 24–48 hours [29][38][40][43]. After the highest-risk period, tracheostomy is favoured to support long-term airway care and rehabilitation.

This framework reflects general guideline-based principles and must be individualised to the patient's coronary anatomy, antithrombotic regimen, neurological trajectory, and institutional capabilities. All decisions should be made in close collaboration with the treating cardiologist. This is general medical education, not patient-specific advice.